IAG Cargo has reported a 22% year-over-year increase in tonnage for its Constant Climate product in 2024, highlighting the rising need for temperature-controlled air freight in the pharmaceutical sector.
Read also: Why Demand for Cold Chain Logistics in Pharmaceuticals is Growing Rapidly
Designed to transport critical medical products like vaccines, biotech materials, and diagnostic samples, Constant Climate plays a crucial role in the pharma supply chain. Nearly half of these shipments originated from India and Ireland, both of which have seen significant growth in pharmaceutical exports.
Jordan Kohlbeck, Head of Pharmaceutical at IAG Cargo, emphasized the importance of secure, temperature-controlled logistics, stating, “Ensuring life-saving medicines and treatments reach patients in optimal condition is more important than ever. We continue to invest in our facilities and workforce to meet this growing demand.”
Recent industry data reflects this expansion:
- Ireland’s medical and pharmaceutical exports rose by €2.9 billion (+48%) in January 2024 compared to the previous year, making up nearly half of the country’s total exports.
- India’s drug and pharma exports increased from $2.13 billion in 2023 to $2.31 billion in 2024, accounting for 20% of the global pharma supply chain.
IAG Cargo has also expanded its Constant Climate network, adding approved stations in Cincinnati, Cape Town, and Strasbourg. Additionally, the opening of the New Premia facility at London Heathrow has doubled its cool chain storage and handling capacity, reinforcing IAG Cargo’s position as a key player in pharmaceutical logistics.
With global pharma demand accelerating, IAG Cargo remains committed to providing reliable, temperature-controlled solutions to ensure medicines reach patients safely and efficiently.
